Author Archive

Your Guide to the 2024 Combination Products Summit: Agenda, Insights, and What to Anticipate

Agenda and Expectations for the 2024 Combination Products Summit: Navigating the Future of Healthcare

The healthcare landscape is constantly evolving, and with it, the need for innovative solutions in combination products—those unique blends of drugs, devices, and biologics that present distinct challenges for development and commercialization. The 2024 Combination Products Summit is the premier event where industry leaders, regulators, and experts come together to tackle these challenges head-on.

This year’s summit promises to be more impactful than ever, offering a comprehensive agenda that will equip professionals with the knowledge and tools they need to navigate the complexities of combination products in a dynamic regulatory environment.

Read more »

ComplyFDA Presents: Baseline Assessment

Enhancing Quality Processes: ComplyFDA’s Insightful Approach to Baseline Assessments

Recently, Michael Kuehne at ComplyFDA conducted a deep dive into developing a baseline assessment using a risk-based approach looking at all quality processes. This approach delivers actionable improvement recommendations and incorporates validated best practices to ensure robust solutions. I found this analysis extremely insightful and wanted to share it with you: Read more »

Navigating the Complex Landscape of Combination Product Regulations

Elisa Kim, Mike Wallenstein, John “Barr” Weiner and Khaudeja Bano spoke at the Combination Products Summit. Source: Michele G. Sullivan

Insights From Combination Products Summit

The journey of developing and commercializing combination drug/device products is filled with challenges, primarily due to the non-harmonized global regulatory frameworks. As discussed at the recent 2023 Combination Products Summit, manufacturers face significant hurdles because different countries have their own definitions and requirements for these products. This lack of uniformity complicates the application process, adding layers of complexity and burdening manufacturers. Read more »

Quality Solutions Now Turns 20!

Celebrating 20 Years of Excellence and Innovation!

Twenty years ago, Quality Solutions Now (QSN) embarked on a mission to create a world where health is protected and promoted through the manufacturing of safe and effective medical products. From our humble beginnings in October 2004, QSN has seen tremendous growth, now serving a diverse range of clients in the medical device, drug, and biologic manufacturing sectors.

As we celebrate our 20th anniversary, we reflect on our journey and the remarkable milestones we’ve achieved. Here’s a look at our progress:  Read more »

Announcing QSN and ComplyFDA Partnership!

Quality Solutions Now and ComplyFDA Partnership

Leading the Way in Life Sciences Compliance and Quality Management

Quality Solutions Now (QSN) and ComplyFDA have joined forces to offer unparalleled solutions in quality management and regulatory compliance for the life sciences industry. This collaboration enhances our capabilities in providing comprehensive, scalable, and cost-effective solutions, ensuring clients meet and exceed quality and regulatory standards. Read more »

ISO 13485:2016 rewrites the standard for medical device manufacturing

A risk-based approach to QMS. If you’re a manufacturer of medical devices, including the medical device portion of combination products this is not the first time you’ve encountered this emphasis; the shift towards Quality by Design (QbD) has placed risk assessment and management at the forefront of compliance and regulatory considerations for organizations operating within the life sciences industries. But ISO 13485:2016 and its quickly approaching requirements for certification have brought risk front and center for medical device manufacturers with a renewed urgency. Read more »

Quality by Design paves the way for innovation

For companies in the Life Sciences industry, today’s climate—a mixture of competition, regulation, increasing consumer awareness, and continually evolving knowledge and capabilities—presents manufacturers of pharmaceuticals, medical devices, biologics, and combination products with a choice: maintain the status quo in product design, manufacture, and testing, or join the forward motion of the industry as well as the FDA in embracing the holistic and dynamic approach of Quality by Design (QbD). Read more »

Using the FDA’s data on citations to guide compliance efforts

“It’s a full thickness tear of your right rotator cuff.”

Not words I ever wanted to hear, let alone leading up to a holiday. But this diagnosis gave me the opportunity to consider the safety and efficacy of the medical devices and drugs involved in its treatment on a personal level, from the standpoint of the end user.

My pre-Christmas surgery comprised arthroscopic repair to shave the bone and enable greater range of motion for the rotator cuff, a fixation device and suturing to repair the torn tendon, and drugs to anesthetize, manage pain, and ward off infection. It was followed by six weeks with my right arm in a sling, and 12 weeks of physical therapy.  

For those of us working in the Life Sciences industry, it’s common to view our own medical conditions, or those of family members, through the lens of our work. And that’s exactly what I found myself doing during those months of treatment, recovery, and rehabilitation. “What company made this fixation device?” I found myself wondering. “Do they have any citations from the FDA?” “What about the company that made the pain medication I’m using?” Read more »

Spreading the holiday spirit in the workplace

We are well under way this holiday season! The holidays can mean so many different things to different people; for some, it can be a somber time, remembering the loved ones that are no longer with them. For others it can be a festive time, with gifts, eggnog by the fire and holiday decorations. What do the holidays mean to you? What do you reflect upon or celebrate during the holidays? Read more »